Review
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Aug 15, 2021; 13(8): 799-821
Published online Aug 15, 2021. doi: 10.4251/wjgo.v13.i8.799
B7 homologue 3 as a prognostic biomarker and potential therapeutic target in gastrointestinal tumors
Petar Rasic, Maja Jovanovic-Tucovic, Marija Jeremic, Slavisa M Djuricic, Zorica V Vasiljevic, Maja Milickovic, Djordje Savic
Petar Rasic, Maja Milickovic, Djordje Savic, Department of Abdominal Surgery, Mother and Child Health Care Institute of Serbia “Dr. Vukan Cupic“, Belgrade 11 000, Serbia
Maja Jovanovic-Tucovic, Marija Jeremic, Institute of Medical and Clinical Biochemistry, School of Medicine, University of Belgrade, Belgrade 11 000, Serbia
Slavisa M Djuricic, Department of Clinical Pathology, Mother and Child Health Care Institute of Serbia “Dr. Vukan Cupic“, Belgrade 11 000, Serbia
Slavisa M Djuricic, Faculty of Medicine, University of Banja Luka, Banja Luka 78 000, Bosnia and Herzegovina
Zorica V Vasiljevic, Department of Clinical Microbiology, Mother and Child Health Care Institute of Serbia “Dr. Vukan Cupic“, Belgrade 11 000, Serbia
Maja Milickovic, Djordje Savic, School of Medicine, University of Belgrade, Belgrade 11 000, Serbia
Author contributions: Rasic P, Jovanovic-Tucovic M, and Jeremic M drafted the manuscript; Djuricic SM, Vasiljevic ZV, Milickovic M, and Savic D substantively revised the manuscript; all authors read and approved the final version of the manuscript.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Petar Rasic, MD, Doctor, Department of Abdominal Surgery, Mother and Child Health Care Institute of Serbia “Dr. Vukan Cupic“, Radoja Dakica 6-8, Belgrade 11 000, Serbia. petar.rasic@imd.org.rs
Received: February 20, 2021
Peer-review started: February 20, 2021
First decision: April 6, 2021
Revised: April 19, 2021
Accepted: July 7, 2021
Article in press: July 7, 2021
Published online: August 15, 2021
Processing time: 174 Days and 15.3 Hours
Core Tip

Core Tip: Limitations related to oncotherapy and poor survival of patients with advanced forms of the most common malignant tumors of the gastrointestinal tract, including colorectal, gastric, and esophageal cancers (ECs), have led researchers to investigate new molecular target-driven therapeutic approaches. B7 homologue 3 (B7-H3) was shown to be significantly overexpressed among various malignancies and associated with their progression, metastasis and resistance to anticancer therapy. In this review, we analyze the results of different studies related to B7-H3 in colorectal, gastric, and ECs and suggest that this molecule could be a promising prognostic biomarker and therapeutic target in these tumors.